These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 25912697)
1. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure. Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697 [TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations. Dahlke M; Ng D; Yamaguchi M; Machineni S; Berger S; Canadi J; Rajman I; Lloyd P; Pang Y J Clin Pharmacol; 2015 Apr; 55(4):415-22. PubMed ID: 25408331 [TBL] [Abstract][Full Text] [Related]
3. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M; Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816 [TBL] [Abstract][Full Text] [Related]
4. Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial. Corcoran D; Radjenovic A; Mordi IR; Nazir SA; Wilson SJ; Hinder M; Yates DP; Machineni S; Alcantara J; Prescott MF; Gugliotta B; Pang Y; Tzemos N; Semple SI; Newby DE; McCann GP; Squire I; Berry C Cardiovasc Res; 2021 Jan; 117(1):320-329. PubMed ID: 32065620 [TBL] [Abstract][Full Text] [Related]
5. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence. Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514 [TBL] [Abstract][Full Text] [Related]
6. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Teerlink JR; Voors AA; Ponikowski P; Pang PS; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Gimpelewicz C; Boer-Martins L; Wernsing M; Hua TA; Severin T; Metra M Eur J Heart Fail; 2017 Jun; 19(6):800-809. PubMed ID: 28452195 [TBL] [Abstract][Full Text] [Related]
7. Effects of Serelaxin in Patients with Acute Heart Failure. Metra M; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Voors AA; Adams KF; Anker SD; Arias-Mendoza A; Avendaño P; Bacal F; Böhm M; Bortman G; Cleland JGF; Cohen-Solal A; Crespo-Leiro MG; Dorobantu M; Echeverría LE; Ferrari R; Goland S; Goncalvesová E; Goudev A; Køber L; Lema-Osores J; Levy PD; McDonald K; Manga P; Merkely B; Mueller C; Pieske B; Silva-Cardoso J; Špinar J; Squire I; Stępińska J; Van Mieghem W; von Lewinski D; Wikström G; Yilmaz MB; Hagner N; Holbro T; Hua TA; Sabarwal SV; Severin T; Szecsödy P; Gimpelewicz C; N Engl J Med; 2019 Aug; 381(8):716-726. PubMed ID: 31433919 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU. Maggioni AP; López-Sendón J; Nielsen OW; Hallén J; Aalamian-Mattheis M; Wang Y; Ertl G Eur J Heart Fail; 2019 Mar; 21(3):322-333. PubMed ID: 30604559 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial. Sato N; Lam CS; Teerlink JR; Greenberg BH; Tsutsui H; Oh BH; Zhang J; Lefkowitz M; Hua TA; Holbro T; Marshood M; Wang XL; Ge J J Card Fail; 2017 Jan; 23(1):63-71. PubMed ID: 27825893 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Ponikowski P; Mitrovic V; Ruda M; Fernandez A; Voors AA; Vishnevsky A; Cotter G; Milo O; Laessing U; Zhang Y; Dahlke M; Zymlinski R; Metra M Eur Heart J; 2014 Feb; 35(7):431-41. PubMed ID: 24255129 [TBL] [Abstract][Full Text] [Related]
11. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR; J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292 [TBL] [Abstract][Full Text] [Related]
12. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Metra M; Ponikowski P; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Hua TA; Severin T; Unemori E; Voors AA; Teerlink JR Eur Heart J; 2013 Oct; 34(40):3128-36. PubMed ID: 23999454 [TBL] [Abstract][Full Text] [Related]
13. Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. Teerlink JR; Davison BA; Cotter G; Maggioni AP; Sato N; Chioncel O; Ertl G; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Edwards C; Senger S; Teichman SL; Nielsen OW; Voors AA; Metra M Eur J Heart Fail; 2020 Feb; 22(2):315-329. PubMed ID: 31886953 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study. Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105 [TBL] [Abstract][Full Text] [Related]
15. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. Filippatos G; Farmakis D; Metra M; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua TA; Pang PS; Ponikowski P; Qian M; Severin TA; Voors AA; Teerlink JR Clin Res Cardiol; 2017 Jun; 106(6):444-456. PubMed ID: 28150186 [TBL] [Abstract][Full Text] [Related]
16. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. Liu LC; Voors AA; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Chen Y; Greenberg BH; Ponikowski P; Pang PS; Prescott MF; Hua TA; Severin TM; Metra M Clin Res Cardiol; 2016 Sep; 105(9):727-37. PubMed ID: 27017514 [TBL] [Abstract][Full Text] [Related]
17. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. Felker GM; Teerlink JR; Butler J; Hernandez AF; Miller AB; Cotter G; Davison BA; Filippatos G; Greenberg BH; Ponikowski P; Voors AA; Hua TA; Severin TM; Unemori E; Metra M J Am Coll Cardiol; 2014 Oct; 64(15):1591-8. PubMed ID: 25301463 [TBL] [Abstract][Full Text] [Related]